Overview

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Status:
Completed

Trial end date:
2015-11-05

Target enrollment:

Participant gender:

Summary

This 2-part study will determine the bioavailability of BMS-626529 in healthy subjects from prototype low dose extended release formulations (Part 1) of BMS-663068 and prototype extended release multi-particulate formulations (Part 2) of BMS-663068 relative to 600 mg extended release tablet of BMS-663068.

Phase:

Phase 1

Details

Lead Sponsor:

Bristol-Myers Squibb
ViiV Healthcare

Collaborator:

GlaxoSmithKline

Treatments:

Fostemsavir